Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Regeneron Pharmaceuticals Inc — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.75 (market cap $141.25M), while Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 539× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| KOLD | REGN | |
|---|---|---|
Market Cap | $141.25M | $76.14B |
Volume | 5,492,367 | 500,239 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $852.03 |
52-Week Low | $13.58 | $557.73 |
Typical Hold Time | 10 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD trades at $24.75, down 0.36% with bearish technical signals from moving averages. The stock faces pressure from record-high natural gas production and mild weather forecasts, though geopolitical tensions in the Middle East provide some support. Technical indicators show oversold conditions with RSI at 31.97, while support levels are established at $23-$25.
The outlook remains cautious with bearish technical momentum and fundamental headwinds from oversupply concerns. Near-term catalysts include geopolitical developments and winter demand, but elevated production levels and storage capacity constraints present significant downside risks for energy sector investors.
Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.
The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
